Proline News and Research

RSS

Study uses computational modeling of coronavirus spike proteins to examine dynamics responsible for immunogenicity and immune escape

A new study published on the bioRxiv* preprint server focused on the development of dynamic computational models for a large subset of S proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2.

23 Aug 2021

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

New research, available as a preprint on the bioRxiv* server, has focused on the role played by T cell immunity, particularly CD8+ cytotoxic T cells, on preventing lethal infection with SARS-CoV-2 in mice infused with peptide-loaded antigen-presenting dendritic cells (DCs).

19 Aug 2021

SARS-CoV-2 variants and their ability to infect mice

A new study published on the bioRxiv* preprint server has conducted in silico studies along with in vitro, in vivo, and in situ observations and indicated the mouse adaptation of SARS-CoV-2.

10 Aug 2021

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

New insights on replication-stress sensitivity in breast cancer cells

Oncotarget published "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity" which reported that these authors recently documented that gain-of-function mutant p53 R273H in triple negative breast cancer cells interacts with replicating DNA and PARP1.

28 Jul 2021

A small molecule inhibitor shows promise to reduce the growth of uveal melanoma

Uveal melanoma, or UM, is a rare and deadly cancer of the eye, and the mortality rate has remained unimproved for 40 years. Half of the melanomas spread to other organs of the body, causing death in less than a year, so new treatments to preserve vision and prevent death are an urgent need.

15 Jul 2021

RUDN University doctors find alterations in serum amino acid profile in children with ADHD

RUDN University doctors found alterations in serum amino acid profile in children with attention deficit hyperactivity disorder (ADHD).

17 Jun 2021

New mouse model mimics human pathology of childhood restrictive cardiomyopathy

Severe childhood restrictive cardiomyopathy is a condition that causes the muscles in the walls of the heart to become stiff, so that the heart is unable to fill properly with blood.

17 Jun 2021

New color-changing thread in tampons or sanitary napkins helps diagnose vulvovaginal yeast infections

The yeast Candida albicans can cause itchy, painful urinary tract and vaginal yeast infections. For women in low-resource settings who lack access to healthcare facilities, these infections create substantial social and economic burdens.

20 May 2021

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

The importance of computational modeling in the prediction of the course of the ongoing COVID-19 pandemic, as well as evaluating multiple potential drug leads, has never been more clear. Now, a new study describes a set of designer vaccine antigens that may improve vaccine stability as well as enhance the neutralizing antibody response.

13 May 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine

A new preprint research paper posted to the medRxiv* server reports on vaccine resistance data that pushes the end of the pandemic further away.

6 Apr 2021

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

Novel SARS-CoV-2 spike vaccine candidate produces strong neutralizing response in vivo

A new study by researchers at Mahidol University in Bangkok, Thailand, reports a COVID-19 vaccine candidate called HexaPro in producing neutralizing antibodies against the SARS-CoV-2 spike protein in an animal model.

3 Mar 2021

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

The primary aim of any vaccine is to stimulate immune functions and confer long-lasting protection. A paper recently uploaded to the preprint server bioRxiv by Tong et al. (17th Feb 2021) describes a novel vaccine utilizing PIKA adjuvant and recombinant spike proteins against COVID-19 disease that promises the generation of potent neutralization antibodies, which potentially support immune responses for years.

21 Feb 2021

Study reveals new molecular mechanism linked to severe anaphylaxis

Anaphylaxis is a systemic allergic reaction that can affect the skin, the gastrointestinal tract, the respiratory system and the cardiovascular system.

9 Feb 2021

Highly conserved neutralizing epitope identified on SARS-CoV-2 spike protein

A recent study conducted at the University of Texas at Austin, USA, has identified a highly conserved neutralizing antibody binding site on the spike S2 domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study findings might help develop novel spike-targeting antibodies for widespread protection. The study is currently available on the bioRxiv preprint server.

2 Feb 2021

Inhaled single dose vaccine creates antibodies and prevents infection in rhesus macaques

Now, a new preprint research paper describes a chimpanzee adenovirus-vectored vaccine that, when administered intranasally in rhesus macaques, led to a robust immune response and demonstrated protection against infection by the virus that causes COVID-19, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The preprint is published on the bioRxiv server.

1 Feb 2021